Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634172 | 0.79 | SLC6A2 (0.45) | KIF11SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL25008509 | 0.75 | VNN1 (0.48) | KIF11SLC6A2SLC6A3CHRNA1CHRNG | |
| SCHEMBL769904 | 0.74 | EPHX2 (0.43) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL5510929 | 0.72 | NPC1 (0.45) | KIF11MEN1KMT2AVNN1NPC1 | |
| SCHEMBL25007317 | 0.72 | CES1 (0.48) | KIF11VNN1NPC1RAB9AERCC5 | |
| SCHEMBL6763904 | 0.71 | CES1 (0.47) | CYP2C19HRH1OPRK1KCNH2CYP2B6 | |
| SCHEMBL28993105 | 0.71 | NPC1 (0.44) | KIF11MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL22313259 | 0.70 | GRIN1 (0.56) | SLC6A2SLC6A3CHRNA1CHRNGITGA5 | |
| SCHEMBL1264958 | 0.70 | CES1 (0.44) | HRH1KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL27363440 | 0.69 | SCN5A (0.43) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919841-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | RES TRIANGLE INST (US) | 2018-08-02 | — | — | US | disclosed |
| US-9562001-B2 | Monoamine reuptake inhibitors | RESEARCH TRIANGLE INSTITUTE (US) | 2017-02-07 | — | — | US | disclosed |
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE | 2012-03-22 | — | — | US | disclosed |
| EP-2419400-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121022-A1 | MONOAMINE REUPTAKE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071560-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | KIF11 2911/4885SLC6A2 1/4885SLC6A3 3/4885 |
| US-10919841-B2 | Monoamine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | KIF11 2911/4885SLC6A2 1/4885SLC6A3 3/4885 |
| US-20180215701-A1 | MONOAMINE REUPTAKE INHIBITORS | SLC6A2, SLC6A4, SLC6A3 | KIF11 2911/4885SLC6A2 1/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.